Cannabidiol (CBD)

How to discuss CBD and answer questions frequently asked by patients

Jason Mitchell, board-certified naturopathic doctor, co-founder and CEO of HempFusion Wellness Inc, dives into the world of cannabinoids and what's on the horizon for CBD.

OTC CBD is often touted for its uses in pain management, anxiety relief, and sleep. But the popular cannabinoid has been shown to benefit women’s health, too––an opportunity that pharmacies can leverage as a cash-based revenue strategy.

Although nearly 70% of the population cohort had conditions requiring medications, there was no increase in the number of reported adverse events while taking CBD products.

BioLyte Laboratories and Honest Globe have 15 days to rectify the violations from their CBD products.

In a presentation from APhA2021, clinical pharmacist Danielle Fixon, PharmD, BCGP, BCPS, offers counseling tips for CBD products.

Results of a study presented in a poster presentation during ASHP Midyear collected data of the available OTC CBD products being sold in Colorado pharmacies.

Survey results presented during the ASHP 2020 Midyear Clinical Meeting and Exhibition offered insight into community pharmacists’ knowledge and confidence of CBD products.

Although the booming demand can make CBD products a profitable addition to any pharmacy inventory, some questions remain about the legal compliance factors.

Tips for building financial success with CBD for your pharmacy.

As the use of CBD-containing products continues to rise, pharmacists need to be familiar with the clinical implications of CBD use, especially in patients who use other pharmacologically active substances.

What pharmacists need to consider before selling CBD in their stores.

By 2029, the global market for cannabinoid-based pharmaceuticals will reach $50 billion.

CBD and its impacts on a protective peptide show that the cannabinoid may reduce lung inflammation and damage.

The FDA approved a cannabidiol oral solution treatment (Epidiolex, Greenwich Biosciences) for seizures associated with tuberous sclerosis complex.

Responding to growing interest by industry stakeholders, the agency has offered draft guidance outlining quality considerations and other practical recommendations for cannabis and cannabis-derived compounds.

A systematic review of medical cannabis and cannabinoid use in oncology care demonstrated varied results. 

Cannabidiol oral solution (Epidiolex, GW Pharmaceuticals) is no longer considered a controlled substance.

Strategies for seizing revenue opportunities outside of the PBM.

A supplemental application for cannabidiol oral solution (Epidiolex, GW Pharmaceuticals and Greenwich Biosciences) has been submitted for the treatment of seizures associated with tuberous sclerosis complex.

Takeaways from a roundtable at ASHP 2019.

The FDA issued warning letters to several companies marketing their CBD products in ways that violate the Federal Food, Drug, and Cosmetic Act.

Site will offer CBD education and product marketing.

Fifth company warned about unsubstantiated claims this year.

CBD market will grow by over 700% in 2019.

Despite legal restrictions and insufficient regulation, the market for CBD oil is booming. 

Lack of regulation means protecting public health is pharmacist's duty. 

The CBD market is anticipated to be worth $20 billion by 2024.

The FDA recently approved cannabidiol oral solution to treat seizures.